A concern that drug companies cannot ignore

摘要

A report by the House of Commons Health Committee into the influence of the UK pharmaceutical industry has recommended that companies should publish the results of all their trials and follow guidelines for responsible publication practice.1 Cynics may argue that such reports rarely have much influence over powerful commercial companies and that governments usually ignore their recommendations unless they support existing policies. But this call for greater transparency and responsibility echoes similar calls which, taken together, form a crescendo that is hard to ignore.